Acta Scientific Gastrointestinal Disorders (ASGIS)(ISSN: 2582-1091)

Case Report Volume 3 Issue 12

Vitiligo Improvement in Patient with Crohn’s Disease Undergoing Treatment with Infliximab

Cardoso Mateus Ricardo1*, Tavares Isabela Boulhosa1, Cordeiro Karina Ferreira1 and Campos Luciana Teixeira2

1Medical Student at Centro Universitário de Brasília - UniCEUB, Faculdade de Ciências da Educação e Saúde - FACES, Brasília, Distrito Federal, Brazil
2Professor at UniCEUB e Master in Health Sciences, Gastroenterologist at Instituto Hospital de Base do Distrito Federal - IHB-DF, Brasília, Distrito Federal, Brazil

*Corresponding Author: Cardoso Mateus Ricardo, Medical Student at Centro Universitário de Brasília - UniCEUB, Faculdade de Ciências da Educação e Saúde - FACES, Brasília, Distrito Federal, Brazil.

Received: November 10, 2020; Published: November 28, 2020

×

Abstract

Introduction: Vitiligo is a skin disease that causes depigmentation due to the destruction of epidermal melanocytes. The etiology of vitiligo is unknown, and it is mainly related to an autoimmune factor, coursing with imbalance of cytokines in the injured areas. Infliximab is an anti-TNF-α antibody that prevents the binding of TNF-α to its receptors, this can cause both a protective effect and an inducing effect on the autoimmunity of vitiligo.

Objective: Report a case of improvement of vitiligo after treatment with Infliximab and review the existing literature on this subject.

Method: Case report selected due the improvement of vitiligo after the use of Infliximab by means of the analysis of medical records, followed by a bibliographic review in textbooks and Pubmed and Google Scholar databases, which results in a qualitative and exploratory analysis of the literature.

Results: Description of the improvement of a patient with vitiligo after six months of treatment with Infliximab used for Crohn’s disease.

Conclusion: Anti-TNF-α agents have been a promising method for the treatment of vitiligo, especially in refractory cases. Infliximab, however, has presented controversial results in the literature, such as aggravation of the condition or onset cases. The results of this report raises suspicions about the effects of TNF-α inhibition of vitiligo’s pathophysiology, therefore the role of Infliximab as a treatment form remains questionable.

Keywords: Vitiligo; Infliximab; Crohn’s Disease; Case Reports; Tumor Necrosis Factor-Alpha

×

References

  1. Luber RP., et al. “New onset vitiligo following commencement of Infliximab in Crohn disease”. Journal of Internal Medicine 8 (2017): 972-973.
  2. Ryu T H., et al. “A Type II Segmental Vitiligo Developed under Infliximab Treatment for Ulcerative Colitis”. A Dermatologist 6 (2017): 826-827.
  3. Simón J A and Burgos-Vargas R. “Vitiligo improvement in a patient with ankylosing spondylitis treated with Infliximab”. Dermatology 3 (2008): 234-235.
  4. Lee S H., et al. “Psoriasis, Vitiligo and Crohn's Disease Co-Existingin a Single Patient: A Variant Type of Multiple Autoimmune Syndrome?” A Dermatologist 6 (2017): 782-785.
  5. Lv Y., et al. “Use of anti-tumor necrosis factor agents: a possible therapy for vitiligo”. Medical Hypotheses 5 (2009): 546-547.
  6. Ramírez-Hernandez M., et al. “Infliximab-induced vitiligo”. Dermatology 1 (2005): 79-80.
  7. Webb KC., et al. “Tumour necrosis fator-α inhibition can stabilize disease in progressive vitiligo”. British Journal of Dermatology 3 (2015): 641-650.
  8. Posada C., et al. “Vitiligo during treatment of Crohn’s disease with adalimumab: adverse effect or co-occurrence”. Case Reports in Dermatology 1 (2011): 28-31.
  9. Bellet J S and Prose NS. “Vitiligo em crianças: uma revisão de classificação, hipóteses sobre patogênese e tratamento”. Anais Brasileiros de Dermatologia 6 (2005): 631-636.
  10. Carvalho CLDB and Ortigosa LCM. “Segmental vitiligo after Infliximab use for rheumatoid arthritis-A case report”. Anais Brasileiros de Dermatologia 1 (2014): 154-156.
×

Citation

Citation: Cardoso Mateus Ricardo., et al. “Vitiligo Improvement in Patient with Crohn’s Disease Undergoing Treatment with Infliximab". Acta Scientific Gastrointestinal Disorders 3.12 (2020): 30-33.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor0.835

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 15, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US